L'intérêt à découvert pour Akero Therapeutics donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Akero Therapeutics. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Akero Therapeutics (NASDAQ:AKRO) Stock, Rapport sur les intérêts à découvert

AKERO THERAPEUTICS INC

Akero Therapeutics

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

Equinix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQIX#NASDAQ">EQIX</a>) has outperformed the market over the past 20 years by 6.94% on an annualized basis producing an average annual return of 15.44%. Currently, Equinix has a market capitalization of $76.60 billion. 
Buying $1000 In EQIX: If an investor had bought $1000 of EQIX stock 20 years ago, it would be worth $17,641.78 today based on a price of $787.00 for EQIX at the time of writing.
<h3>Equinix's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751575513_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

EQIX

Here's How Much $1000 Invested In Equinix 20 Years Ago Would Be Worth Today

On June 30, 2025, the Board of Directors of Sharps Technology, Inc. (the "Company") appointed Paul Danner to serve as the Company's Executive Chairman, replacing Soren Christiansen, who was a non-executive Chairman.
&nbsp;
In connection with Mr. Danner's appointment and resulting change in independence status, the Board appointed Timothy Ruemler to serve as Chairman of the Audit Committee. Additionally, the Board appointed Soren Christiansen to fill Mr. Danner's seat on the Compensation Committee.

Management

STSS

Sharps Technology Appoints Paul Danner As Executive Chairman

On July 1, 2025, Beam Therapeutics Inc. (the "Company") entered into an Agreement and Plan of Merger pursuant to which it acquired an early-stage life sciences company (the "Agreement"). As consideration for the acquisition, the Company agreed to issue to the shareholders of the company (i) 403,128 shares of the Company's common stock, par value $0.01 per share (the "Common Stock") as an upfront payment (the "Upfront Shares") and (ii) up to an aggregate of $89,000,000 in potential additional payments upon the achievement of certain development, clinical and commercial milestones, which milestone payments may be made in cash or in shares of Common Stock (the "Milestone Shares") in the Company's sole discretion. Based on the closing price of the Common Stock of $17.01 per share on June 30, 2025, the maximum number of Milestone Shares issuable pursuant to the Agreement is 5,232,216 shares; however, the exact number of Milestone Shares cannot be determined at this time, and the Company intends to file an amendment to this Form 8-K to disclose the exact number of Milestone Shares issued, if any. The issuance of the Upfront Shares and any Milestone Shares that the Company elects to issue in satisfaction of milestone payments will not be registered under the Securities Act of 1933, as amended (the "Securities Act"), or any state securities laws. Based in part upon the representations of the shareholders of the company in the Agreement, the Company has relied on the exemption from the registration requirements of the Securities Act under Section 4(a)(2) thereof for a transaction by an issuer not involving any public offering.&nbsp;

BEAM

Beam Therapeutics Enters Agreement To Acquire Early-Stage Life Sciences Company For 403,128 Upfront Shares And Up To $89M In Milestone Payments

Preliminary Q2 2025 Operating Results
Emeren is also providing its preliminary financial updates for the second quarter of 2025. Based on currently available information, the Company expects the following:
<ul>
<li>A non-cash impairment of no less than $20 million on global property, plant, and equipment (PPE), primarily reflecting an updated fair value assessment of certain power station assets in accordance with U.S. GAAP.</li>
</ul>

Guidance

Emeren Expects A Non-Cash Impairment Of No Less Than $20M On Global Property, Plant, And Equipment

Investor Kevin O&#8217;Leary, who just finished taping &#8220;a big chunk&#8221; of Season 17 of &#8220;Shark Tank,&#8221; says it&#8217;s shaping up to be one of the most exciting yet.&nbsp;
It&#8217;s also the first without longtime shark Mark Cuban, who has <a href="https://www.benzinga.com/general/entertainment/25/05/45472538/mark-cuban-bids-farewell-to-shark-tank-how-to-watch-finale-and-whats-next-for-hit-show">announced</a> he would be leaving the show after Season 16. His absence marks a major shift, but the energy on set remains high, according to O&#8217;Leary.
<h2 class="wp-block-heading">Big Companies, Bigger Problems</h2>
&#8220;The market for venture capital has dried up,&#8221; O&#8217;Leary said in a recent <a href="https://x.com/kevinolearytv/status/1938382234798715257">post on X</a>. &#8220;It reminds me of 2008, 2009.&#8221;
Don't Miss:
<ul class="wp-block-list">
<li>Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. <a href="https://www.benzinga.com/money/this-company-may-have-found-a-way-to-treat-cancer-by-tricking-the-bodys-immune-system-and-early-studies-show-some-promise-find-out-how-you-can-invest-in-the-future-of-cancer-treatment">Back a bold new approach to cancer treatment with high-growth potential.</a></li>
<li>Named a TIME Best Invention and Backed by 5,000+ Users, Kara's Air-to-Water Pod Cuts Plastic and Costs — <a href="https://www.benzinga.com/money/americans-spend-1000-per-year-on-plastic-water-bottles-kara-pod-gives-you-clean-drinking-water-by-pulling-moisture-from-the-air">And You Can Invest At Just $6.37/Share</a></li>
</ul>
According to O&#8217;Leary, even large companies with solid sales are now turning to &#8220;Shark Tank&#8221; to <a href="https://www.benzinga.com/personal-finance/25/06/46034399/startup-investing-used-to-be-for-millionaires-not-anymore">raise money</a> and get global exposure. &#8220;They just can&#8217;t raise money and so they&#8217;re coming to the &#8216;Shark Tank&#8217; for two things: to get that global exposure, it&#8217;s in 154 countries, and of course to seek capital,&#8221; he said.
O&#8217;Leary added that the show has been attracting a wider range of businesses, including those already generating serious revenue. &#8220;Every year seems to be the same. The deals get bigger and the companies get larger.&#8221;
He said this season is packed with innovation, including healthy food alternatives, tech, and even artificial intelligence. &#8220;I keep saying this every year: this is the best year ever,&#8221; he said. &#8220;The number of innovation, companies, like just huge. Really interesting.&#8221;
Trending: Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation. </a>&nbsp;
<h2 class="wp-block-heading">His Advice for Entrepreneurs? Just Start</h2>
In another recent <a href="https://x.com/kevinolearytv/status/1938345869071298659">post</a>, O&#8217;Leary addressed the uncertainty of today's economy, especially with crypto booming, interest rates fluctuating, and geopolitical risks piling up. His advice to new entrepreneurs is simple: just start.
&#8220;More than half the time [successful companies are founded] in times of extreme stress or volatility,&#8221; he said. &#8220;It really doesn&#8217;t have a good or bad time to start — it&#8217;s just start is what you have to do.&#8221;
He also pointed out that failure is a constant part of entrepreneurship. &#8220;The <a href="https://www.benzinga.com/news/topics/25/06/45772125/90-of-startups-fail-heres-whats-going-wrong">majority of the startups fail</a> anyways, and they always have since the 1950s when they&#8217;ve been tracking venture capital,&#8221; he noted.
See Also: Tired of Grid Failures and Charging Deserts? This Startup Has a Solar Fix and $25M+ in Sales — <a href="https://www.benzinga.com/money/meet-the-company-seeking-to-give-americans-energy-independence-and-learn-how-you-can-become-an-early-investor">Now Raising at $3/Share</a>
Still, he said, the journey often pays off. &#8220;The nature of the journey is exactly that — it&#8217;s never a destination. It&#8217;s a journey,&#8221; O&#8217;Leary said.
For many entrepreneurs, he added, the payoff comes later in the form of a buyout, going public, or getting acquired. &#8220;And then they just get back on the road and continue the journey.&#8221;
Read Next: <a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a>
Image: Shutterstock

Kevin O'Leary Says The Venture Capital Market Has 'Dried Up' Like In 2008. Now Even Big Companies Are Coming On 'Shark Tank' For Funding

Quantum computing stocks had a big week with a completed offering and bullish analyst coverage<a href="https://www.benzinga.com/trading-ideas/movers/25/07/46193784/d-wave-quantum-stock-is-trading-higher-tuesday-whats-happening"> of several stocks.&nbsp;</a>
Here&#8217;s a look at the highlights, lowlights and news catalysts in the quantum computing sector.
<h3 class="wp-block-heading">D-Wave Quantum &#8211; QBTS&nbsp;</h3>
D-Wave Quantum, Inc. (NYSE: QBTS) announced on Tuesday that <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46193784/d-wave-quantum-stock-is-trading-higher-tuesday-whats-happening" target="_blank" rel="noopener">it had </a><a href="https://www.benzinga.com/trading-ideas/movers/25/07/46193784/d-wave-quantum-stock-is-trading-higher-tuesday-whats-happening">successfully </a>sold $400 million of its common stock, completing the offering at an average price of $15.18 per share.
On Wednesday, Cantor Fitzgerald analyst Troy Jensen <a href="https://www.benzinga.com/analyst-stock-ratings/initiation/25/07/46232263/d-wave-surges-1326-whats-driving-quantum-computings-newest-star">initiated coverage</a> on D-Wave Quantum with an Overweight rating and a $20 price target. 
Read Next:<a href="https://www.benzinga.com/analyst-stock-ratings/upgrades/25/07/46245952/metas-growth-sizzles-but-wait-for-a-pullback-before-buying-in?utm_source=articleShare"> Meta&#8217;s Growth Sizzles, But Wait For A Pullback Before Buying In</a>
Jensen said the company is in the very early innings of commercializing its technology and is positioned to capture 15% of the quantum hardware, software and services market by 2035.&nbsp;&nbsp;
D-Wave Quantum stock has gained 16% over the past five days.&nbsp;&nbsp;
<h3 class="wp-block-heading">Rigetti Computing &#8211; RGTI&nbsp;</h3>
Cantor&#8217;s Jensen also<a href="https://www.benzinga.com/analyst-stock-ratings/initiation/25/07/46230597/quantum-computings-dark-horse-rigetti-stands-at-the-edge-of-greatness"> initiated coverage</a> on Rigetti Computing, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) with an Overweight rating and a bullish $15 price target.
The analyst noted that after challenging years in 2022 and 2023, Rigetti's share price has rallied since late 2024, increasing by approximately 1,008% over the last 52 weeks.
He also applauded Rigetti's partnership with Quanta Computer and sees the collaboration helping to accelerate the development and commercialization of superconducting quantum computing.&nbsp;
<h3 class="wp-block-heading">IonQ&nbsp;&#8211; IONQ</h3>
IonQ, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) shares rallied about 11% this week. The stock also received a Buy rating<a href="https://www.benzinga.com/analyst-stock-ratings/initiation/25/07/46229237/cash-rich-ionq-to-capture-20-of-quantum-market-by-2035-analyst"> from Cantor</a> and a $45 price forecast. 
Jensen pointed to IonQ's strong financial position, noting that the company ended the first quarter of 2025 with nearly $700 million in cash following a $373 million equity raise.
<h3 class="wp-block-heading">Quantum Computing &#8211; QUBT</h3>
QUBT: The Cantor analyst initiated coverage on Quantum Computing, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) with a Neutral rating and a $15 price target, well below the stock's current $20 levels. However, the stock remained strong with gains of 67.5% over the past month and over 4,600% in the past year. 
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/07/46236537/openai-says-tokens-are-not-equity-no-partnership-with-robinhood-musk-says-ai-companys-equity-is-fake?utm_source=articleShare">OpenAI Says Tokens Are Not Equity, No Partnership With Robinhood: Musk Says AI Company&#8217;s Equity &#8216;Is Fake&#8217;</a></li>
</ul>
Image: Shutterstock

Initiation

Analyst Ratings

Movers

Tech

IONQ

QBTS

QUBT

RGTI

Quantum Stock Watch: Bullish Analyst Coverage On IonQ, D-Wave, Rigetti Computing

Autodesk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) has outperformed the market over the past 10 years by 7.87% on an annualized basis producing an average annual return of 19.69%. Currently, Autodesk has a market capitalization of $67.39 billion. 
Buying $1000 In ADSK: If an investor had bought $1000 of ADSK stock 10 years ago, it would be worth $5,942.20 today based on a price of $315.00 for ADSK at the time of writing.
<h3>Autodesk's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751574617_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADSK

Here's How Much $1000 Invested In Autodesk 10 Years Ago Would Be Worth Today

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed up 60.00% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/BLGVF">Belgravia Hartford Cap</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BLGVF#OTC">BLGVF</a>) shares closed up 22.01% at $0.25</li>
<li><a href="https://www.benzinga.com/quote/CURR">Currenc Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) shares closed up 16.32% at $1.04</li>
<li><a href="https://www.benzinga.com/quote/CBWTF">Auxly Cannabis Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBWTF#OTC">CBWTF</a>) shares closed up 14.50% at $0.09</li>
<li><a href="https://www.benzinga.com/quote/ITHUF">iAnthus Capital Hldgs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ITHUF#OTC">ITHUF</a>) shares closed up 8.70% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/TLRY">Tilray Brands</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) shares closed up 8.18% at $0.54</li>
<li><a href="https://www.benzinga.com/quote/CGC">Canopy Growth</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) shares closed up 7.62% at $1.28</li>
<li><a href="https://www.benzinga.com/quote/NWVCF">EnWave</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NWVCF#OTC">NWVCF</a>) shares closed up 7.10% at $0.29</li>
<li><a href="https://www.benzinga.com/quote/UGRO">Urban-gro</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) shares closed up 5.31% at $0.31</li>
<li><a href="https://www.benzinga.com/quote/OILFF">Nextleaf Solutions</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OILFF#OTC">OILFF</a>) shares closed up 3.58% at $0.05</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/CNBX">CNBX Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNBX#OTC">CNBX</a>) shares closed down 25.00% at $0.0009</li>
<li><a href="https://www.benzinga.com/quote/LBUY">Leafbuyer Techs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LBUY#OTC">LBUY</a>) shares closed down 13.04% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/BBRRF">Blueberries Medical</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BBRRF#OTC">BBRRF</a>) shares closed down 10.00% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/LVRLF">CordovaCann</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LVRLF#OTC">LVRLF</a>) shares closed down 8.29% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/CNTMF">FLUENT</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTC">CNTMF</a>) shares closed down 7.12% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/ZDPY">Zoned Properties</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ZDPY#OTC">ZDPY</a>) shares closed down 6.40% at $0.54</li>
<li><a href="https://www.benzinga.com/quote/YCBD">cbdMD</a> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) shares closed down 6.40% at $0.86</li>
<li><a href="https://www.benzinga.com/quote/RIV">Rivernorth Opps Fund</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RIV#NYSE">RIV</a>) shares closed down 4.46% at $12.35</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cannabis

Markets

BBRRF

BLGVF

CANNABIS WHEATON INCOME by Cannabis Wheaton Income Corp.

CBWTF

CNBX

CNTMF

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

FFNTF

ITHUF

LEAFBUYER TECHNOLOGIES by Leafbuyer Technologies, Inc.

LBUY

LVRLF

NWVCF

OILFF

TLRY

UGRO

YCBD

ZDPY

Bullish Sentiment Across The Cannabis Space - Check Full Movers For July 3, 2025

As previously disclosed, on June 10, 2025, Jean-Marc Bellemin notified Iovance Biotherapeutics, Inc. (the "Company") that he would be resigning as Chief Financial Officer and Principal Financial Officer and Principal Accounting Officer of the Company to pursue other opportunities, effective July 10, 2025. On June 30, 2025, the Company and Mr. Bellemin mutually agreed that Mr. Bellemin would separate from the Company, effective June 30, 2025.
&nbsp;
Effective as of June 30, 2025, Matthew W. Rosinack, the Company's Senior Vice President, Finance, was appointed as the Company's interim Principal Financial Officer and Principal Accounting Officer.

IOVA

Iovance Biotherapeutics CFO Jean-Marc Bellemin Departs Early; Matthew Rosinack Appointed Interim CFO And Principal Accounting Officer

Antero Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AR#NYSE">AR</a>) has outperformed the market over the past 5 years by 50.28% on an annualized basis producing an average annual return of 65.07%. Currently, Antero Resources has a market capitalization of $11.70 billion. 
Buying $1000 In AR: If an investor had bought $1000 of AR stock 5 years ago, it would be worth $12,587.84 today based on a price of $37.62 for AR at the time of writing.
<h3>Antero Resources's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751573712_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Antero Resources Stock In The Last 5 Years

On July 3, 2025, Lantern Pharma Inc., a Delaware corporation (the "Company"), entered into an ATM Sales Agreement (the "Sales Agreement") with ThinkEquity LLC (the "Agent"), pursuant to which the Company may offer and sell up to $15,530,000 maximum aggregate offering price of shares (the "Placement Shares") of common stock, par value $0.0001 per share, of the Company ("Common Stock") from time to time through the Agent, acting as sales agent or principal, in such amounts as the Company may specify by notice to the Agent, in accordance with the terms and conditions set forth in the Sales Agreement.

Offerings

LTRN

Lantern Pharma Enters $15.53M At-The-Market Offering Agreement With ThinkEquity

SHIM

Shimmick Files For Stock Shelf Of Up To $20M

ASST

Asset Entities Enters Amended Merger Agreement On June 27, 2025; Strive Stockholders To Receive Merger Consideration; Merger End Date Extended To February 6, 2026

MingZhu Logistics Holdings Limited ("MingZhu" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YGMZ#NASDAQ">YGMZ</a>), an elite provider of logistics and transportation services to businesses, today announced it has entered into a Share Purchase Agreement (the "SPA") to acquire 100% equity of Shenzhen Mingzhuchun Wine Co., Ltd. ("Mingzhuchun"), which operates its liquor distribution business through its two subsidiaries Xiamen Bainian Qianzhuang Wine Group Co., Ltd. and Ningde Mingfu Wine Co., Ltd. in China.
Under the SPA, MingZhu shall acquire 100% of Mingzhuchun in exchange for the issuance of 2,000,000 ordinary shares of Mingzhu upon closing. The shareholder of Mingzhuchun shall receive additional First Earnout Payment of 2,000,000 ordinary shares and Second Earnout Payment of 2,000,000 ordinary shares respectively if the net income of Mingzhuchun is no lower than US$1 million for the fiscal year 2025 and 2026 respectively.
The closing of the transaction contemplated by the SPA is subject to the satisfaction of the closing conditions set forth therein.

YGMZ

MingZhu Logistics To Acquire Mingzhuchun Wine Co. In Exchange For The Issuance Of 2M Ordinary Shares Of Mingzhu Upon Closing; Additional First Earnout Payment Of 2M Ordinary Shares And Second Earnout Payment Of 2M Ordinary Shares Respectively If The Net Income Of Mingzhuchun Is No Lower Than $1M For The Fiscal Year 2025 And 2026 Respectively

Despite a <a href="https://www.benzinga.com/markets/economic-data/25/07/46244105/june-jobs-report-nonfarm-payroll-adp-data">better-than-expected jobs report</a> sending the major indices higher, multinational food company Kraft Heinz Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KHC#NASDAQ">KHC</a>) conspicuously lost a relatively sizable portion of its market value during Thursday afternoon trading. While nonfarm payrolls increasing by 147,000 in June represented the strongest reading so far in 2025, it wasn't enough to convince investors to buy KHC stock. Still, that just might change for the better.
Undoubtedly, the Trump administration has sparked massive changes across the board. However, the food industry in particular has been <a href="https://www.benzinga.com/general/health-care/25/05/45560572/rfk-jr-s-make-america-healthy-again-report-stirs-gop-farmers-over-glyphosate-concerns-ahead-of-release">under the spotlight</a> thanks to Health and Human Services Secretary Robert F. Kennedy Jr. With his "Make America Healthy Again" initiative, Kennedy aimed the spotlight on <a href="https://www.benzinga.com/markets/equities/25/03/44209953/rfk-jr-takes-on-food-giants-calls-meeting-with-pepsico-and-general-mills">processed food concerns</a>.
To be sure, Kraft Heinz faces other challenges besides the political headwind. Nevertheless, the impact to KHC stock cannot be ignored. Since the 2024 presidential election, KHC has dropped around 20%, reflecting investor concerns about how the underlying company can adapt to the new public health framework.
Investors will receive greater clarity on July 30, when the food producer is scheduled to release its <a href="https://www.benzinga.com/quote/KHC/earnings">earnings</a> results for the second quarter. In the meantime, there's reason for optimism despite the ugly erosion of KHC stock.
Last month, Kraft Heinz announced that it would <a href="https://www.benzinga.com/markets/large-cap/25/06/45980305/kraft-heinz-bans-artificial-colors-in-us-products-eyes-full-phaseout-by-2027">not launch any new products</a> in the U.S. that incorporate chemical dyes listed under the Food, Drug, and Cosmetic (FD&amp;C) Act. The company will also remove remaining FD&amp;C colors from its U.S. product portfolio before the end of 2027. Per The New York Times, the move came two months after Kennedy moved to <a href="https://www.nytimes.com/2025/06/17/business/kraft-heinz-chemical-food-dyes.html">ban</a> artificial food dyes.
However, nearly 90% of Kraft Heinz's U.S. product lineup was already free of FD&amp;C colors. Not only that, the company has been making efforts to remove artificial colors since 2016, in response to shifting consumer preferences.
It's possible, then, that the market has been overreacting to some of the pessimistic press that the food industry has been receiving.
<h2 class="wp-block-heading">Playing The Numbers Game With KHC Stock</h2>
As intriguing as a fundamental narrative may be, the approach lacks specificity — the very quality that options traders need. When it comes to trading in the derivatives market, a thesis can't just be accurate regarding the magnitude component (y-axis); it must also meet the profitability threshold within the given time period (x-axis).
To better guide the decision-making process, traders need to apply statistical analysis. Here, the temptation is to merely take the frequency of the desired outcome divided by the total number of events in the dataset. But this approach only calculates the derivative probability or outcome odds across the dataset's entire distribution. What traders really need is the conditional probability — outcome odds across a specific subset of the data.
To use a baseball analogy, derivative probabilities are akin to a player's career batting average. They provide a baseline expectation. Conditional probabilities represent situational batting averages, such as how a player stacks up against specific pitchers. It's entirely possible that an otherwise mediocre player just has an ability to wreak havoc on certain opponents.
Still, to quantify whether an advantage exists for a particular situation, the underlying metric must be the same. For example, one can't compare baseball stats with those of cricket. To that end, the conversion of price action into market breadth — or sequences of accumulative and distributive sessions — pancakes continuous scalar signals into distinct, discrete events.
Using this framework, the price action of KHC stock in the trailing two months can be denoted as a "3-7-D" sequence: three up weeks, seven down weeks, with a negative trajectory across the 10-week period. Admittedly, this conversion process compresses KHC's magnitude dynamism into a simple binary code. But the benefit is that market behaviors can be segregated into distinct demand profiles. Further, these profiles can be studied for their transitional likelihood, opening the door to conditional probabilistic analysis.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03150442/KHC-stock-10wk-forecast-1024x576.jpg" alt="" class="wp-image-972579" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03150442/KHC-stock-10wk-forecast-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03150442/KHC-stock-10wk-forecast-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03150442/KHC-stock-10wk-forecast-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03150442/KHC-stock-10wk-forecast.jpg 1280w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Image by author</figcaption></figure>
Since January 2019, the 3-7-D sequence has flashed 35 times. In 62.86% of cases, the price action for the following week (which corresponds with the business week beginning July 7) results in upside, with a median return of 1.84%.
Assuming that KHC stock ends this holiday-shortened week around $26.70, the security should be able to pop its head above the $27 level relatively quickly. If the bulls maintain control of the market for two weeks, past analogs imply a push toward $27.50.
<h2 class="wp-block-heading">Taking A Swing At Kraft Heinz Options</h2>
For those seeking a quick hit, the 26.50/27.50 bull call spread expiring July 18 presents a risky but enticing idea. This transaction involves buying the $26.50 call and simultaneously selling the $27.50 call, for a net debit paid of $45, the most that can be lost in this trade. Should KHC stock rise through the short strike price ($27.50) at expiration, the maximum reward is $55, a payout of over 122%.
Another approach is to consider the 27/28 bull spread expiring Aug. 1. This trade requires a net debit of $46 with a maximum reward of $54, a payout of over 117%. While there's greater time for this bullish thesis to pan out, the spread is highly dependent on the second-quarter earnings results (assuming a hold to expiration).
Either way, the bullish strategy is compelling because of the implied shift in sentiment regime of the 3-7-D sequence. As a baseline, the chance that KHC stock will rise on any given week is only 49.71%. In recent years, KHC hasn't been a great trade for the bulls. However, circumstances appear to be statistically different at this moment, thus incentivizing a speculative posture.
The opinions and views expressed in this content are those of the individual author and do not necessarily reflect the views of Benzinga. Benzinga is not responsible for the accuracy or reliability of any information provided herein. This content is for informational purposes only and should not be misconstrued as investment advice or a recommendation to buy or sell any security. Readers are asked not to rely on the opinions or information herein, and encouraged to do their own due diligence before making investing decisions.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/options/25/07/46232821/gtlb-stock-tactical-edge-game-theory">Options Corner: GitLab Could Offer Traders A Tactical Edge Through Applied Game Theory</a></li>
</ul>
Photo: Shutterstock

Equities

Long Ideas

Options

Options Corner: Why Kraft Heinz Could Flip The Script On The Bears

Wall Street loves a good comeback tale, and June&#8217;s <a href="https://www.benzinga.com/etfs">ETF flows</a> provided just that. With $102.7 billion in net inflows, according to FactSet data, the U.S. ETF business rebounded from its April slowdown, posting a 17% increase over May and taking total assets under management to $11.5 trillion. But the real tale? A few ETFs and issuers have left everyone else in the dust, flashing neon signs that investors are wagering on high-beta (highly volatile) funds.
Also Read: <a href="https://www.benzinga.com/etfs/specialty-etfs/25/05/45680211/3-high-beta-etfs-to-consider-as-wall-street-welcomes-court-ruling-on-tariffs-tech-rebound">3 High Beta ETFs To Consider As Wall Street Welcomes Court Ruling On Tariffs, Tech Rebound</a>
<h2 class="wp-block-heading">High-Conviction Inflows</h2>
Rafferty Asset Management booked a stunning $256.6 million in June inflows, a 730% recovery from May&#8217;s painful outflow of more than $40 million. Close behind was Tuttle Capital, taking in $68.7 million, another flip after a drubbing in May. Toroso Investments generated $7.8 million in new inflows, a small but significant amount.
What&#8217;s driving it? A league of single-stock and leveraged ETFs that are high-risk, high-reward, and extremely popular today.
Eight issuers launched 23 <a href="https://www.benzinga.com/etfs/new-etfs/25/07/46203728/quantum-ai-nuclear-three-frontiers-one-launchpad-powered-by-defiance-etfs" target="_blank" rel="noopener">new single-stock ETFs in June</a> — a notable increase. They are not for the weak of heart: 75% are geared (leveraged/inverse) and target tactical, high-conviction trades. Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Palantir (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) and MicroStrategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) continue to be investor favorites, receiving the most issuer attention.
<h2 class="wp-block-heading">Funds That Dominated In June</h2>
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<thead>
<tr>
<th>Fund</th>
<th>Type</th>
<th>June Net Flow</th>
</tr>
</thead>
<tbody>
<tr>
<td>Direxion Daily TSLA Bull 2X Shares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSL#NASDAQ">TSL</a>)</td>
<td>Leveraged</td>
<td>$134.9 million</td>
</tr>
<tr>
<td>YieldMax MSTR Option Income ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSTY#NYSE">MSTY</a>)</td>
<td>Single-Stock</td>
<td>$83.9 million</td>
</tr>
<tr>
<td>GraniteShares 2x Long PLTR ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIR#NASDAQ">PTIR</a>)</td>
<td>Leveraged</td>
<td>$34.9 million</td>
</tr>
<tr>
<td>T-Rex 2x Long NVDA ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/NVDX#BATS">NVDX</a>)</td>
<td>Leveraged</td>
<td>$52.8 million</td>
</tr>
<tr>
<td>Direxion AAPL Bull 2X ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPU#NASDAQ">AAPU</a>)</td>
<td>Leveraged</td>
<td>$45.3 million</td>
</tr>
<tr>
<td>Direxion MSFT Bull 2X ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFU#NASDAQ">MSFU</a>)</td>
<td>Leveraged</td>
<td>$39.6 million</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Source: FactSet</figcaption></figure>
Altogether, these six ETFs collectively brought in more than $391 million in June, predominantly from leveraged bets on the large-cap tech giants.
Looking at year-to-date inflows, FactSet revealed:
<ul class="wp-block-list">
<li>TSL (Tesla 2X) tops YTD flows with $310.8 million.</li>
<li>MSTY (MicroStrategy option income) takes second with $198 million.</li>
<li>PTIR (Palantir 2X) is not far behind at $98.6 million.</li>
</ul>
<h2 class="wp-block-heading">Sector Signals: Where The Money Is Heading</h2>
June&#8217;s sector flows told a distinct story: investors are gravitating back into Tech, Consumer Discretionary, and Communication Services— all areas connected to AI, platforms, and online consumption. 
Financials, Energy, and Health Care experienced ongoing outflows, meanwhile. This was evident from the $707 million inflows recorded in SPDR Select Sector Fund &#8211; Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>), $459 million in Materials Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>) and $601 million in the Communication Services Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>). 
Conversely, $1.5 billion flowed out of SPDR Select Sector Fund &#8211; Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>), $303 million from SPDR Select Sector Fund &#8211; Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) and $661 million from SPDR Select Sector Fund &#8211; Health Care (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>).
And while fixed income flows fell 16% to $32 billion, equity flows rose 29% to $57 billion, showing that investors aren&#8217;t quite risk-averse, but are merely growing more discerning.
<h2 class="wp-block-heading">Watch The Leaders, Read The Signals</h2>
Although June&#8217;s overall inflows were robust, it&#8217;s the degree to which investor money has flowed into a handful of high-beta ETFs that&#8217;s most illustrative. It is a sign of unprecedented conviction, not merely in big tech and AI, but in tactical, aggressive investing. Whether the giants of this rally can sustain their dominance will be determined by macro tailwinds and how long this momentum mojo can last.
For the time being, the message from ETF land is unmistakable: risk is back on, primarily for those fearless enough to ride it 2X.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/bonds/25/07/46252249/vanguard-plans-low-cost-junk-bond-etf-as-demand-for-high-yield-grows">Vanguard Plans Low-Cost Junk Bond ETF As Demand For High-Yield Grows</a></li>
</ul>
Photo: NicoElNino via Shutterstock

Sector ETFs

Specialty ETFs

ETFs

AAPU

MSFU

MSTR

Tidal Trust II YieldMax MSTR Option Income Strategy ETF

MSTY

NVDA

ETF Opportunities Trust T-Rex 2X Long NVIDIA Daily Target ETF

NVDX

PLTR

PTIR

TSLA

Tesla, Nvidia, Palantir ETFs Dominate As Traders Pile Into High-Risk Bets In June

Linkage Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGCB#NASDAQ">LGCB</a>) reported quarterly losses of $(0.90) per share. This is a 34.33 percent decrease over losses of $(0.67) per share from the same period last year. The company reported $3.502 million in sales this quarter. This is a 27.01 percent decrease over sales of $4.798 million the same period last year.

Earnings

LGCB

Linkage Global H1 EPS $(0.90) Down From $(0.67) YoY, Sales $3.502M Down From $4.798M YoY

Throughout the last three months, 11 analysts have evaluated Moodys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCO#NYSE">MCO</a>), offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">9</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $523.0, a high estimate of $573.00, and a low estimate of $456.00. Highlighting a 3.88% decrease, the current average has fallen from the previous average price target of $544.09. 
<img src="https://www.benzinga.com/files/images/story/2025/1751572930_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Moodys among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Haas</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$573.00</td>
<td>$572.00</td>
</tr>
<tr>
<td>Owen Lau</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$552.00</td>
<td>$523.00</td>
</tr>
<tr>
<td>Owen Lau</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$523.00</td>
<td>$489.00</td>
</tr>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$550.00</td>
<td>$550.00</td>
</tr>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$550.00</td>
<td>$550.00</td>
</tr>
<tr>
<td>Owen Lau</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$489.00</td>
<td>$523.00</td>
</tr>
<tr>
<td>Shlomo Rosenbaum</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$468.00</td>
<td>$533.00</td>
</tr>
<tr>
<td>Jeffrey Silber</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$456.00</td>
<td>$475.00</td>
</tr>
<tr>
<td>Jeffrey Meuler</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$525.00</td>
<td>$575.00</td>
</tr>
<tr>
<td>Jason Haas</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$572.00</td>
<td>$610.00</td>
</tr>
<tr>
<td>Andrew Steinerman</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$495.00</td>
<td>$585.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Moodys. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Moodys compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Moodys's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Moodys's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MCO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Moodys analyst ratings.</a>
<h2>Unveiling the Story Behind Moodys</h2>
Moody's, along with S&amp;P Ratings, is a leading provider of credit ratings on fixed-income securities. The ratings segment, Moody's Investors Service, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's profit and about half of the firm's revenue. The other segment, Moody's Analytics, consists of decision solutions, research and insights, and data and information.
<h3>Moodys's Financial Performance</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Positive Revenue Trend: Examining Moodys's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 7.73% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.
Net Margin: Moodys's net margin excels beyond industry benchmarks, reaching 32.48%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Moodys's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 17.21%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Moodys's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 4.08%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a high debt-to-equity ratio of 1.93, Moodys faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>What Are Analyst Ratings?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Moodys Stands With Analysts

<ul>
<li>Mark Higson joins as Chief Operating Officer, Steve Vellacott joins as VP, Airworthiness &amp; Head of Design Organisation, and Eric Samson named VP Programme-Hybrid</li>
<li>Strengthened leadership team will support operational, commercial, and technological advancements as Vertical accelerates towards global certification and commercialisation</li>
</ul>
Vertical Aerospace (Vertical) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVTL#NYSE">EVTL</a>), a global aerospace and technology company that is pioneering electric aviation, today announced the addition of key executives to its leadership team as the Company accelerates through its Flightpath 2030 goals.
Stuart Simpson, CEO of Vertical Aerospace, said: "These appointments further reinforce our leadership bench as we accelerate into our next phase of growth and global deployment. Mark and Steve bring decades of deep operational and engineering expertise that will be instrumental in driving the certification and commercialisation of the VX4 at scale. Eric's focused leadership, technical insight, and deep certification experience will be invaluable as we advance our hybrid-electric VX4 strategy and expand our market potential."
Mark Higson joins as Chief Operating Officer and is a seasoned executive with significant expertise in developing operational and commercial strategies, leading complex, global organisations through transformational change. He has over four decades of experience across international businesses, most recently serving as Chief Executive Officer of Modulaire Group, a global leader in modular services and infrastructure, where he successfully led the sale and refinancing of the business. Originally an Aerospace Engineer, Mark started his career at British Aerospace subsequently serving in senior operational leadership roles across the industrials sector, including at Wolseley UK and the Royal Mail, and as a senior advisor to McKinsey &amp; Company and to Advent International's portfolio companies.
Steve Vellacott joins as VP of Airworthiness &amp; Head of Design Organisation, bringing decades of experience in structural engineering and design, including significant expertise leading electric and other complex VTOL programmes. He joins Vertical from Lilium where he was Chief Technology Officer and Head of Design, overseeing the team responsible for the design, development and certification of its eVTOL aircraft. Prior to Lilium, Steve spent over three decades at Leonardo Helicopters, holding a variety of leadership roles across its international civil and military programmes, where he worked closely with EASA around certification and compliance of the aircraft. He was elected as a Fellow of the Royal Aeronautical Society in 2018.
Eric Samson named as VP Programme-Hybrid, building on the Company's <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fvertical-aerospace.com%2Fwp-content%2Fuploads%2F2025%2F05%2FVertical-Aerospace-Announces-1000-mile-Hybrid-Electric-VTOL-Programme-to-Serve-Defence-Logistics-and-Wider-Commercial-Markets.pdf&amp;esheet=54285764&amp;newsitemid=20250703192539&amp;lan=en-US&amp;anchor=recently+announced&amp;index=1&amp;md5=8af0467e6facc0b680a11334709d06b4">recently announced</a> hybrid-electric VTOL aircraft strategy. Ericis a proven aerospace leader with extensive experience in aircraft design and systems integration. Since joining Vertical in 2020, he has served as Senior Vice President of Engineering and Head of Design Organisation, leading Vertical's Engineering and Design Organisation to design, build, test and prepare to certify the VX4 . Prior to Vertical, Eric held various technical and leadership roles, including at Jet Aviation and Gulfstream Aerospace.
The expansion of Vertical's leadership team builds on the Company's significant momentum and progress towards delivering a scalable, certifiable aircraft to the global market. Vertical remains on track to complete its test flight program in 2025, having recently achieved the first piloted wingborne flight of a winged eVTOL in European public airspace.

EVTL

Vertical Aerospace Announces Mark Higson Joins Co As Chief Operating Officer

Across the recent three months, 14 analysts have shared their insights on Olin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLN#NYSE">OLN</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">12</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $23.57, with a high estimate of $34.00 and a low estimate of $19.00. Observing a downward trend, the current average is 17.3% lower than the prior average price target of $28.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1751572895_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Olin among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$23.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Michael Leithead</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$24.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Angel Castillo</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$20.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Duffy Fischer</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$25.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Jeffrey Zekauskas</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$20.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$22.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Peter Osterland</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$24.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$25.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$22.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Aleksey Yefremov</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$34.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Peter Osterland</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$25.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$19.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$21.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Charles Neivert</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$26.00</td>
<td>$33.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Olin. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Olin compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Olin's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Olin's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/OLN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Olin analyst ratings.</a>
<h2>Delving into Olin's Background</h2>
Olin Corp manufactures and sells a variety of chemicals and chemical-based products. The company organizes itself into three segments based on the product type. The Chlor alkali products and Vinyls segment, which generates the majority of revenue, sells chlorine and caustic soda, which are used in a variety of industries including cosmetics, textiles, crop protection, and fire protection products. The Epoxy segment sells epoxy resins used in paints and coatings. The Winchester segment sells sporting ammunition and ammunition accessories under the Winchester brand. The majority of revenue comes from the United States.
<h3>Financial Milestones: Olin's Journey</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Positive Revenue Trend: Examining Olin's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 0.54% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. When compared to others in the Materials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Olin's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.07% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Olin's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 0.06%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Olin's ROA excels beyond industry benchmarks, reaching 0.02%. This signifies efficient management of assets and strong financial health.
Debt Management: With a high debt-to-equity ratio of 1.66, Olin faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>How Are Analyst Ratings Determined?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Olin: Insights From 14 Analyst Reviews

Legal

Press Releases

INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Akero Therapeutics, Inc. to Contact Law Firm

Health Care

Akero Therapeutics Announces Upcoming Poster and Oral Presentations at the EASL Congress 2025

Long-Term Shareholders Have Rights – If You Hold Akero Therapeutics, Inc. (NASDAQ: AKRO); Integra Lifesciences Holdings Corporation (NASDAQ: IART); Mercury Systems, Inc. (NASDAQ: MRCY); or Virtu Financial Inc. (NASDAQ: VIRT), Contact Grabar Law Office

Akero Therapeutics to Present at the BofA Securities 2025 Healthcare Conference

Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025

Comments

Akero Therapeutics

Intérêt court

Akero Therapeutics (NASDAQ:AKRO) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL